Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Overview of Bremer Pharma GmbH
Bremer Pharma GmbH is an important pharmaceutical intermediary based in Bremerhaven, Bremen. The company was founded with the goal of creating a reliable interface between pharmaceutical manufacturers, importers, and wholesalers. It brings extensive expertise in pharmaceutical wholesale and intermediary trade and utilizes the excellent logistical infrastructure of the port city of Bremerhaven to offer its services efficiently.
Pharmaceutical Intermediation in the North Sea Region
As a pharmaceutical intermediary, Bremer Pharma focuses on the rapid and flexible procurement of regular pharmaceuticals as well as hard-to-obtain specialized preparations. The company plays a crucial role in the supply of medications by ensuring that the availability of life-saving medicines is maintained even in times of crisis. Registration with the state authority underlines compliance with strict regulatory requirements applicable to pharmaceutical wholesale. Bremer Pharma holds all necessary approvals to operate in this sensitive area, including certificates under the Medicines Act (AMG).
The product portfolio includes prescription medications, over-the-counter drugs, and specialized therapies. Additionally, Bremer Pharma is able to offer customized solutions for individual customer needs, including the procurement of rare medications or innovative therapies as part of its services.
Location Bremerhaven
The location of the company in Bremerhaven is a strategic advantage. As one of the most important German seaports, Bremerhaven offers ideal conditions for the import and export of pharmaceutical products. The port serves not only as a logistics center but also as access to international markets, greatly facilitating Bremer Pharma's operations. The location makes the company a key player in the northern German region, where many pharmaceutical customers rely on efficient logistics solutions.
Bremer Pharma has also established significant partnerships with various regional and international manufacturers. These collaborations strengthen the company's market position and enable quick access to the latest products and technologies. Close cooperation with health authorities and pharmacies ensures that the supply of medications in the region is always guaranteed.
Regulatory Classification and Quality Management
Bremer Pharma GmbH is subject to strict regulatory guidelines set out under the Medicines Act (AMG) and Good Distribution Practice (GDP). The company meets all requirements necessary to ensure the quality, safety, and efficacy of pharmaceuticals. A key component of the corporate culture is the quality management system, which is continuously developed to meet the highest standards.
In addition to quality management, emphasis is placed on the further education and training of employees to ensure that all staff are informed about the latest developments in the field of pharmacy. These measures help ensure that Bremer Pharma GmbH operates at the forefront of technology and science at all times.
Future Perspectives
With a clear focus on innovation and expansion, Bremer Pharma GmbH plans to further expand its network and enter new markets. The increasing importance of digitalization in healthcare opens up new opportunities to optimize supply further and improve customer service. Whether through digital platforms that facilitate access to pharmaceuticals or innovative logistics solutions, the company is relying on future-oriented strategies to strengthen and expand its market position.
More pharmaceutical intermediaries in Germany | pharmaceutical intermediaries in Bremen | pharmaceutical wholesale in Germany
Frequently asked questions about Bremer Pharma GmbH
Was ist Bremer Pharma GmbH?
Bremer Pharma GmbH ist ein pharmazeutisches Unternehmen in Bremerhaven, Bremen, das im pharmazeutischen Handel tätig ist und Transaktionen mit Arzneimitteln koordiniert.
In welcher Branche ist Bremer Pharma GmbH tätig?
Bremer Pharma GmbH ist im pharmazeutischen Sektor tätig, als Arzneimittelvermittler, Händler oder Dienstleister für die Pharmaindustrie in Bremen.
Wie kontaktiere ich Bremer Pharma GmbH?
Die vollständige Adresse und Kontaktdaten von Bremer Pharma GmbH in Bremerhaven, Bremen finden Sie auf dieser Sanoliste-Seite.
Drug Brokers in Germany
Related areas in healthcare
Drug Brokers by location
About Drug Brokers
A medicine broker (Arzneimittelvermittler) is a business that arranges the purchase or sale of human medicines between manufacturers, wholesalers and buyers, acting as an intermediary without ever taking physical possession of or legal title to the products. This role is formally defined under Section 4(22b) of the AMG (German Medicinal Products Act). Medicine brokers play a role in international parallel trade and in secondary supply chains, but their activities are subject to strict legal requirements to prevent counterfeit medicines from entering the legitimate supply chain. In Germany, anyone wishing to act as a medicine broker must register with the competent authority of the relevant German federal state under Section 52b AMG. Registration requires a permanent business address in Germany or another EU member state, a designated responsible person, and a fully documented quality management system that meets the requirements of the EU Good Distribution Practice (GDP) guidelines for medicine brokers. Failure to register or to maintain the required quality system constitutes a criminal offence under German pharmaceutical law. The registration system ensures traceability and accountability throughout the supply chain. Medicine brokers must not procure medicines from unlicensed sources or supply non-authorised products. The GDP requirements specific to brokers include record keeping, complaint handling, recall procedures and counterfeiting detection. This directory lists all medicine brokers registered with German authorities under Section 52b AMG, with addresses and contact details.
Medicine Brokering in Germany: Legal Framework
Medicine brokering is a regulated activity in Germany and across the European Union, governed by the EU Falsified Medicines Directive (2011/62/EU) and its implementing measures, transposed into German law through amendments to the AMG. The formal definition of a medicine broker (Arzneimittelvermittler) is set out in Section 4(22b) AMG: a natural or legal person who arranges transactions involving medicinal products for human use between manufacturers, wholesalers and buyers, without themselves acquiring or supplying the products and without taking physical possession of them. This intermediary role distinguishes brokers from wholesalers. The registration requirement under Section 52b AMG was introduced specifically to increase transparency and traceability in the medicine supply chain, after investigations revealed that unlicensed brokers had been involved in the entry of substandard or falsified medicines into European supply chains. Germany's registration system requires brokers to notify the competent state authority before commencing operations and to maintain their registration as long as they are active.
GDP Quality System Requirements for Medicine Brokers
Although medicine brokers do not physically handle medicines, they are still required to operate a documented quality management system (QMS) under the EU GDP guidelines for brokers (2013/C 343/01, Part III). The QMS must cover several key areas: written procedures (SOPs) for all brokering activities, a system for verifying that all counterpart manufacturers and wholesalers hold the required licences, a complaints handling system for quality-related issues, a product recall procedure that can be activated even though the broker did not physically move the goods, record keeping for a minimum of five years for all brokered transactions, and procedures for detecting and reporting suspected falsified medicines to the competent authority. Brokers must not source from or supply to unlicensed parties. Regular self-inspections and, where relevant, external audits ensure the QMS remains effective. The competent state authority may inspect a broker's QMS as part of its oversight activities.
Medicine Brokering and Parallel Trade in the EU
Medicine brokering is closely associated with parallel trade (Parallelhandel) in the EU pharmaceutical market. Parallel trade occurs when an authorised medicine is purchased in an EU member state where its price is lower and resold in another member state where the price is higher, exploiting price differentials across the single market. Germany, as a large market with relatively higher medicine prices than some southern and eastern European member states, is a significant destination for parallel-traded medicines. Parallel importers must obtain a parallel import permit from BfArM or PEI for each product, ensuring the imported medicine is equivalent to the authorised German version. Medicine brokers can play a role in arranging these cross-border transactions. However, all parties in the parallel trade supply chain, including brokers, must comply with applicable GDP and registration requirements. The Falsified Medicines Directive's safety features (tamper-evident packaging and unique identifiers under the EU Falsified Medicines Verification System, EMVS) apply to all prescription medicines circulating in Germany.
Compliance and GDP Requirements for Brokers
Pharmaceutical brokers remain under strict regulatory oversight despite not handling products physically. A broker's GDP quality system must include procedures for order processing, supplier qualification, complaints management, recall management and self-inspections. All brokered medicinal products must originate from legal, officially approved sources; transaction documentation must be kept comprehensively and retained for at least five years. Suspected falsified medicines must be reported to the competent authority. The European Commission defined clear requirements for brokers without product ownership in GDP Guidelines 2013/C 343/01. Regular self-inspections and the designation of a Responsible Person (RP) are mandatory. Violations can result in deregistration and criminal consequences under the Medicines Act. The Sanoliste directory only lists brokers who were registered in accordance with Section 52b AMG at the time of their entry.
What does a medicine broker do?
A medicine broker, as defined under Section 4(22b) of the AMG (German Medicinal Products Act), arranges transactions in human medicines without taking ownership of the products or physically handling them. Brokers must be registered with the responsible authority and maintain a quality management system.
What registration does a medicine broker need?
Medicine brokers must register under Section 52b AMG with the responsible state authority. Requirements include an official business address in Germany and a documented quality system meeting GDP (Good Distribution Practice) standards.
Where can I find registered medicine brokers in Germany?
The competent state pharmaceutical supervisory authority in each federal state maintains a register of brokers registered under Section 52b AMG. Sanoliste provides a searchable overview of registered medicine brokers across Germany with contact details and addresses.
Why are medicine brokers regulated in Germany?
Regulation of medicine brokers in Germany is primarily aimed at preventing counterfeit and substandard medicines from entering the legitimate pharmaceutical supply chain. By requiring registration and a documented GDP quality system, authorities can trace the origin and movement of medicines arranged by brokers. This protects patients and ensures that only authorised medicines from authorised sources reach pharmacies and hospitals.
What are the GDP requirements for medicine brokers in Germany?
Under EU GDP guidelines (2013/C 343/01), medicine brokers must maintain a quality system that covers written procedures, complaint handling, product recall procedures, record keeping and measures to detect falsified medicines. They must only deal with manufacturers and wholesalers that hold the appropriate authorisations. These requirements apply equally to brokers registered in Germany under Section 52b AMG.
How does medicine brokering differ from pharmaceutical wholesale in Germany?
The key difference is physical possession. A pharmaceutical wholesaler (Pharmagrosshandel) physically stores and ships medicinal products and requires a wholesale dealer authorisation under Section 52a AMG. A medicine broker (Arzneimittelvermittler) never takes possession of the goods; it only acts as an intermediary arranging deals between other parties. Brokers require registration under Section 52b AMG rather than a full wholesale authorisation.